-
Je něco špatně v tomto záznamu ?
First Use of Open-Source Automated Insulin Delivery AndroidAPS in Full Closed-Loop Scenario: Pancreas4ALL Randomized Pilot Study
L. Petruzelkova, V. Neuman, L. Plachy, M. Kozak, B. Obermannova, S. Kolouskova, S. Pruhova, Z. Sumnik
Jazyk angličtina Země Spojené státy americké
Typ dokumentu randomizované kontrolované studie, časopisecké články, práce podpořená grantem
PubMed
36826996
DOI
10.1089/dia.2022.0562
Knihovny.cz E-zdroje
- MeSH
- diabetes mellitus 1. typu * farmakoterapie MeSH
- dospělí MeSH
- hypoglykemika MeSH
- inzulin lidský terapeutické užití MeSH
- inzulin * terapeutické užití MeSH
- inzulinové infuzní systémy MeSH
- klinické křížové studie MeSH
- krevní glukóza MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- pilotní projekty MeSH
- prospektivní studie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
Objective: We evaluated the safety and feasibility of open-source automated insulin delivery AndroidAPS in adolescents and young adults with type 1 diabetes (T1D) and compared its efficacy in three different scenarios: hybrid closed loop (HCL) with meal boluses, meal announcement only (MA), and full closed loop (FCL). Research Design and Methods: In an open-label, prospective, randomized crossover trial (clinicaltrials.gov NCT04835350), 16 adolescents with T1D (10 females) with mean age of 17 years (range 15-20), glycated hemoglobin 56 mmol/mol (range 43-75), and mean duration of diabetes 5.9 years (9-15) underwent three distinct 3-day periods of camp living, comparing the above-mentioned scenarios of AndroidAPS. We used modified and locked version of AndroidAPS 3.1.03, which was called Pancreas4ALL for study purposes. The order of MA and FCL periods was assigned randomly. The primary endpoints were feasibility and safety of the system represented by percentage of time of glucose control by the system and time in hypoglycemia below 3 mmol/L. Results: The glycemia was controlled by the system 95% time of the study and the proportion of time below 3 mmol/L did not exceed 1% over the whole study period (0.72%). The HCL scenario reached significantly higher percentage of time below 3 mmol/L (HCL 1.05% vs. MA 0.0% vs. FCL 0.0%; P = 0.05) compared to other scenarios. No difference was observed among the scenarios in the percentage of time between 3.9 and 10 mmol/L (HCL 83.3% vs. MA 79.85% vs. FCL 81.03%, P = 0.58) corresponding to mean glycemia (HCL 6.65 mmol/L vs. MA 7.34 mmol/L vs. FCL 7.05 mmol/L, P = 0.28). No difference was observed in the mean daily dose of insulin or in the daily carbohydrate intake. No serious adverse event occurred during the study period. Conclusions: Our pilot study showed that FCL might be a realistic mode of treatment for people with T1D.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011598
- 003
- CZ-PrNML
- 005
- 20230801133156.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1089/dia.2022.0562 $2 doi
- 035 __
- $a (PubMed)36826996
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Petruzelkova, Lenka $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000255353474
- 245 10
- $a First Use of Open-Source Automated Insulin Delivery AndroidAPS in Full Closed-Loop Scenario: Pancreas4ALL Randomized Pilot Study / $c L. Petruzelkova, V. Neuman, L. Plachy, M. Kozak, B. Obermannova, S. Kolouskova, S. Pruhova, Z. Sumnik
- 520 9_
- $a Objective: We evaluated the safety and feasibility of open-source automated insulin delivery AndroidAPS in adolescents and young adults with type 1 diabetes (T1D) and compared its efficacy in three different scenarios: hybrid closed loop (HCL) with meal boluses, meal announcement only (MA), and full closed loop (FCL). Research Design and Methods: In an open-label, prospective, randomized crossover trial (clinicaltrials.gov NCT04835350), 16 adolescents with T1D (10 females) with mean age of 17 years (range 15-20), glycated hemoglobin 56 mmol/mol (range 43-75), and mean duration of diabetes 5.9 years (9-15) underwent three distinct 3-day periods of camp living, comparing the above-mentioned scenarios of AndroidAPS. We used modified and locked version of AndroidAPS 3.1.03, which was called Pancreas4ALL for study purposes. The order of MA and FCL periods was assigned randomly. The primary endpoints were feasibility and safety of the system represented by percentage of time of glucose control by the system and time in hypoglycemia below 3 mmol/L. Results: The glycemia was controlled by the system 95% time of the study and the proportion of time below 3 mmol/L did not exceed 1% over the whole study period (0.72%). The HCL scenario reached significantly higher percentage of time below 3 mmol/L (HCL 1.05% vs. MA 0.0% vs. FCL 0.0%; P = 0.05) compared to other scenarios. No difference was observed among the scenarios in the percentage of time between 3.9 and 10 mmol/L (HCL 83.3% vs. MA 79.85% vs. FCL 81.03%, P = 0.58) corresponding to mean glycemia (HCL 6.65 mmol/L vs. MA 7.34 mmol/L vs. FCL 7.05 mmol/L, P = 0.28). No difference was observed in the mean daily dose of insulin or in the daily carbohydrate intake. No serious adverse event occurred during the study period. Conclusions: Our pilot study showed that FCL might be a realistic mode of treatment for people with T1D.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a inzulin $x terapeutické užití $7 D007328
- 650 12
- $a diabetes mellitus 1. typu $x farmakoterapie $7 D003922
- 650 _2
- $a hypoglykemika $7 D007004
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a inzulinové infuzní systémy $7 D007332
- 650 _2
- $a inzulin lidský $x terapeutické užití $7 D061386
- 650 _2
- $a klinické křížové studie $7 D018592
- 650 _2
- $a krevní glukóza $7 D001786
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Neuman, Vit $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Plachy, Lukas $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Kozak, Milos $u IT Department, CLOSED LOOP Systems and Sysop, Prague, Czech Republic
- 700 1_
- $a Obermannova, Barbora $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Kolouskova, Stanislava $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Pruhova, Stepanka $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Sumnik, Zdenek $u Department of Pediatrics, Motol University Hospital, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00173679 $t Diabetes technology & therapeutics $x 1557-8593 $g Roč. 25, č. 5 (2023), s. 315-323
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36826996 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801133153 $b ABA008
- 999 __
- $a ok $b bmc $g 1963810 $s 1197863
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 25 $c 5 $d 315-323 $e 20230313 $i 1557-8593 $m Diabetes technology & therapeutics $n Diabetes Technol Ther $x MED00173679
- LZP __
- $a Pubmed-20230718